Ardelyx Investors May Lead Securities Fraud Lawsuit
Investors who purchased Ardelyx, Inc. stock between January 13, 2025, and August 6, 2026, are invited to step forward as lead plaintiffs in a securities fraud lawsuit. Rosen Law Firm is initiating the action.
The law firm Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Ardelyx, Inc. (NASDAQ: ARDX) common stock. The lawsuit covers the period between January 13, 2025, and August 6, 2026. Interested investors who wish to serve as lead plaintiff must file a motion with the Court by November 16, 2026.
The complaint alleges that Ardelyx's management made overly positive statements to investors while simultaneously disseminating false and misleading information. The lawsuit claims these statements concealed material facts regarding the company's commercial performance and growth prospects for its products XPHOZAH and IBSRELA. Specifically, it cites increasing payer-related access and reimbursement barriers, more stringent prior authorization requirements, and step edit requirements that slowed new patient starts and delayed prescription fulfillment.
Rosen Law Firm states that investors may be entitled to compensation without out-of-pocket fees through a contingency fee arrangement. The firm urges potential class members to contact them for information regarding the class action. While a lawsuit has been filed, a class has not yet been certified. Investors may choose their own counsel or remain an absent class member.
Rosen Law Firm specializes in securities class actions and shareholder derivative litigation, highlighting its track record of recovering substantial sums for investors. The firm advises investors to carefully select counsel.